ライフサイエンスコーパス: nicotine patch

1 curred in 1993 after the introduction of the nicotine patch.

2 rse event rates between e-cigarettes and the nicotine patch.

3 be as effective for smoking cessation as the nicotine patch.

4 utcomes for smoking cessation treatment with nicotine patch.

5 Single-dose (21- or 35-mg) nicotine patch.

6 occasions, in the presence and absence of a nicotine patch.

7 eutical company could market its transdermal nicotine patch.

8 human smokers or in users of the transdermal nicotine patch.

9 human smokers or in users of the transdermal nicotine patch.

10 nd in smokers or in users of the transdermal nicotine patch.

11 g (12.6 +/- 10.1%) and 21-mg (11.8 +/- 9.9%) nicotine patches.

12 king and during treatment with 14- and 21-mg nicotine patches.

13 ine and during treatment with at least 14-mg nicotine patches.

14 y for use in pregnancy is similar to that of nicotine patches.

15 pants comparing refillable e-cigarettes with nicotine patches.

16 ents with ADNFLE who use tobacco products or nicotine patches.

17 (odds ratio [OR] 3.61, 95% CI 3.07 to 4.24), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75

18 245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]), and hea

19 Adding a nicotine patch (15 mg per 16 hours) to behavioral cessat

20 e (21.8%) than for bupropion (16.2%) and the nicotine patch (15.7%).

21 assigned to 8 weeks of treatment with active nicotine patches (15 mg per 16 hours) or matched placebo

22 l-free quitline were sent a 6-week course of nicotine patches (2 weeks each of 21 mg, 14 mg, and 7 mg

23 and C-NRT, 26.8% [113/421]) or at 52 weeks (nicotine patch, 20.8% [50/241]; varenicline, 19.1% [81/4

24 t fast event-related fMRI twice: once with a nicotine patch (21 mg) and once with a placebo patch.

25 y, placebo-controlled and active-controlled (nicotine patch; 21 mg per day with taper) trial of varen

26 ing point-prevalence abstinence at 26 weeks (nicotine patch, 22.8% [55/241]; varenicline, 23.6% [100/

27 ustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine

28 cotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects

29 ne patch plus nicotine lozenge vs 2 weeks of nicotine patch), (3) text-message support (National Canc

30 CI, 1.57-13.15); among participants who used nicotine patches, 30-day continuous abstinence was 5 par

31 to the three interventions (408 placebo, 418 nicotine patch, 420 varenicline).

32 to deliver variable doses matching those of nicotine patches (7, 14 and 21 mg/24 h) and nicotine gum

33 e patch+denicotinized cigarette smoking, (2) nicotine patch+abstinence from smoking, (3) placebo patc

34 Those on bupropion and nicotine patch achieved higher abstinence rates than tho

35 f placebo (placebo pill plus placebo patch), nicotine patch (active patch plus placebo pill), or vare

36 ers and control subjects, implies that acute nicotine patch administration is insufficient to modify

37 triatal circuits, which were not modified by nicotine patch administration.

38 ned to one of three double-blind treatments: nicotine patch alone (control condition); "rescue" treat

39 ence rates at end of treatment were 16% with nicotine patch alone and 28% with bupropion augmentation

40 have failed to achieve abstinence if left on nicotine patch alone by identifying these smokers before

41 blocked randomization to receive either the nicotine patch alone for a standard 10-week, tapering co

42 of smoking cessation than use of either the nicotine patch alone or placebo.

43 assigned to the two rescue treatments or to nicotine patch alone.

44 d efficacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without p

45 omised, placebo-controlled efficacy trial of nicotine patches and a survey of associated resource use

46 There was no association between nicotine patches and MI (OR 0.46; 95% CI: 0.09, 1.47), a

47 placement therapy in the form of transdermal nicotine patches and nicotine gums combined with behavio

48 ipants were allowed to choose varenicline or nicotine patches and were then randomized to adaptive or

49 on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjus

50 Varenicline was more effective than placebo, nicotine patch, and bupropion in helping smokers achieve

51 ficacy and safety of varenicline, bupropion, nicotine patch, and placebo and found a significantly hi

52 eived nicotine replacement therapy (NRT [ie, nicotine patch]), and 265 received placebo.

53 easons and cessation treatments, such as the nicotine patch, are preferentially beneficial to men.

54 For most of the subjects who used the nicotine patch as a smoking cessation aid, urinary total

55 involving more intensive counseling and the nicotine patch as adjuvant therapy are particularly meri

56 vide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cess

57 Nicotine patches, as used in actual practice, do not app

58 Nicotine patch at manufacturer-recommended doses for 10

59 o did not respond adequately to precessation nicotine patch benefited from bupropion augmentation; ab

60 placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief co

61 The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943

62 Each subject (12) received placebo and nicotine patches combined with one of the stimulation pr

63 ated combined treatment with varenicline and nicotine patch compared with placebo and nicotine patch

64 with varenicline and slow metabolisers with nicotine patch could optimise quit rates while minimisin

65 29 adult smokers across four conditions: (1) nicotine patch+denicotinized cigarette smoking, (2) nico

66 was approximately 2-2.4 times the commercial nicotine patch dose as measured by dialysate nicotine fl

67 We investigated the efficacy and safety of nicotine patches during pregnancy.

68 idence interval (CI) excluded an effect from nicotine patches equal to that from cigarette smoking it

69 suggests that combining varenicline with the nicotine patch, extending the duration of varenicline tr

70 l subjects received 8 weeks of a transdermal nicotine patch, five group counseling sessions, and acti

71 corresponded to the higher doses of gum and nicotine patch fluxes.

72 apy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monot

73 for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311).

74 and nicotine patch compared with placebo and nicotine patch for smoking cessation (primary outcome) a

75 ne patch was more effective than placebo and nicotine patch for smoking cessation among smokers who d

76 ed more frequent adverse events than did the nicotine patch for vivid dreams, insomnia, nausea, const

77 HS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks.

78 However, some participants in the nicotine patch group also used e-cigarettes during the s

79 he bupropion group, 25 (2.5%) of 1006 in the nicotine patch group, and 24 (2.4%) of 999 in the placeb

80 he bupropion group, 53 (5.2%) of 1016 in the nicotine patch group, and 50 (4.9%) of 1015 in the place

81 n the placebo group (3.8 percent), 16 in the nicotine-patch group (6.6 percent), 29 in the bupropion

82 group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion grou

83 kg, as compared with a gain of 1.6 kg in the nicotine-patch group, a gain of 1.7 kg in the bupropion

84 Although nicotine patches improve smoking cessation rates, case r

85 n bupropion, using varenicline rather than a nicotine patch in adults with a comorbid psychiatric con

86 tment, varenicline was more efficacious than nicotine patch in normal metabolisers (OR 2.17, 95% CI 1

87 treatment, and 61 participants chose to use nicotine patches, including 31 randomized to adaptive tr

88 g Philadelphia was performed to determine if nicotine patches increase the risk of first MI.

89 d that adaptive treatment using precessation nicotine patches is efficacious for smoking cessation; h

90 Nicotine replacement therapy, in the form of nicotine patches, is commonly offered to pregnant women

91 Their efficacy relative to nicotine patch largely relies on indirect comparisons, a

92 Combination treatment with varenicline and nicotine patch may be a viable option for smokers who dr

93 sation clinical trials and were treated with nicotine patch (n=623), nicotine nasal spray (n=189), bu

94 were randomized to e-cigarettes (n = 569) or nicotine patches (n = 571).

95 ing 1 prequit week; n = 424); and (3) C-NRT (nicotine patch + nicotine lozenge; n = 421).

96 pering course (n = 64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion ad

97 consisted of 196 individuals who received a nicotine patch (NP) and up to 2 pharmacotherapy adaptati

98 There was no effect of the nicotine patch on levels of NNAL plus NNAL-Gluc, indicat

99 otivational counseling; (2) free transdermal nicotine patches on discharge; (3) an offer of free post

100 If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 weeks, the inc

101 moking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241); (2) varenicline only (inc

102 able to varenicline or bupropion relative to nicotine patch or placebo.

103 roxycotinine:cotinine), predicts response to nicotine patch or varenicline for smoking cessation.

104 ated by quitting cigarettes and switching to nicotine patches or by antioxidant vitamin therapy.

105 g, variable puffing frequency, a transdermal nicotine patch, or other nicotine consumption.

106 percent in the group given bupropion and the nicotine patch (P<0.001).

107 ere randomly assigned to receive placebo and nicotine patch (placebo group).

108 ith those reported in previous research, the nicotine patch plus lozenge produced the greatest benefi

109 With such protection, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34,

110 nt therapy intensity (4 weeks of combination nicotine patch plus nicotine lozenge vs 2 weeks of nicot

111 nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nic

112 ble-blind, placebo-controlled treatment with nicotine patch (random assignment).

113 ase bupropion alone or in combination with a nicotine patch resulted in significantly higher long-ter

114 The selected real specimens (nicotine patch, skin exposed to nicotine, fish sauce, an

115 Thirteen used the nicotine patch starting at the quit date, whereas the ot

116 arting 1 week before the target quit date or nicotine patches starting on the target quit day.

117 Nicotine patches substantially increase quit rates among

118 he effect of smoking cessation (3 weeks) and nicotine patch supplementation, (4) the effect of aspiri

119 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine pa

120 Compared to commercial nicotine patches, the device in ON state was approximate

121 dult smokers from the general population for nicotine patch therapy and based the patch dosage on smo

122 hs was more effective than standard-duration nicotine patch therapy for outpatient smokers with medic

123 Tailored nicotine patch therapy for the general population of smo

124 those treated with combined varenicline plus nicotine patch therapy vs varenicline monotherapy, or am

125 Of those subjects not smoking at the end of nicotine patch therapy who entered the relapse preventio

126 For those still smoking at the end of nicotine patch therapy, 3.1% and 0.0% stopped smoking wi

127 At completion of nicotine patch therapy, nonsmoking participants were eli

128 We sought to determine the effects of nicotine patch therapy, when used to promote smoking ces

129 nseling and for health insurance coverage of nicotine patch therapy.

130 1% were abstinent from smoking at the end of nicotine patch therapy.

131 smoking in smokers who stopped smoking with nicotine patch therapy.

132 mong smokers who failed to stop smoking with nicotine patch therapy.

133 daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 thr

134 Addition of the nicotine patch to physician-based smoking cessation coun

135 of 606 cigarette smokers started open-label nicotine patch treatment 2 weeks before the quit date.

136 moking cessation treatment strategy in which nicotine patch treatment was initiated before a quit dat

137 how a sufficient initial response to prequit nicotine patch treatment, combination treatment with var

138 deemed unlikely to achieve abstinence using nicotine patch treatment.

139 of more than 50% in smoking after 1 week of nicotine patch treatment.

140 We calculated the health benefit of nicotine-patch treatment in number of life years that wo

141 t per life year saved by GP counselling with nicotine-patch treatment over GP counselling alone.

142 riple-dummy, placebo- and active-controlled (nicotine patch) trial of varenicline and bupropion for 1

143 tween cigarette smoking or vaping, or during nicotine patch use.

144 ions include using varenicline rather than a nicotine patch, using varenicline rather than bupropion,

145 eive combined treatment with varenicline and nicotine patch (varenicline group), and 61 were randomly

146 oking, 12 weeks of open-label treatment with nicotine patch, varenicline, or C-NRT produced no signif

147 on initial therapeutic response, either the nicotine patch was continued or alternative pharmacother

148 udy, combined treatment with varenicline and nicotine patch was more effective than placebo and nicot

149 ho abstained from smoking, the OR for use of nicotine patches was 0.25 (95% CI: 0.01, 1.67); among th

150 , respectively; the RDs for comparisons with nicotine patch were -1.07 (-2.21 to 0.08) and 0.13 (-1.1

151 -0.24 to 3.81), respectively; the RDs versus nicotine patch were 1.22 (-0.81 to 3.25) and 1.42 (-0.63

152 Behavioral counseling and open-label nicotine patch were also included for the first 4-6 week

153 rs achieve abstinence, whereas bupropion and nicotine patch were more effective than placebo.

154 Nicotine patches, when used to promote smoking cessation

155 way to use NRT is to combine the long-acting nicotine patch with a shorter-acting product (lozenge, g

156 Combining a nicotine patch with other NRT products is more effective

157 ditional recommendations include combining a nicotine patch with varenicline rather than using vareni